Take a step towards the possibility of a better quality of life.

The Company initiated patient enrollment in a pivotal study in North America to assess the safety and efficacy of Augment™ Injectable Bone Graft as a substitute for autograft in foot and ankle fusion procedures. This randomized, controlled study is intended to support Augment™ Injectable product registration in the United States and Canada.  The study will incorporate approximately 300 patients.  Up to 20 clinical centers in North America will be involved, with five sites already approved for enrollment in Canada.   

We have already begun enrolling patients in centers throughout Canada.  Further, we have submitted an Investigational Device Exemption (IDE) to the Food & Drug Administration (FDA) for this study and are currently finalizing the statistical plan. Based on the most recent discussions with the FDA regarding the Augment Injectable study, we expect to begin enrolling patients at our U.S. study sites in the first quarter of 2010 and hope to have the study fully enrolled by the end of the year.

If you have questions regarding the Foot and Ankle Fusion Study, or would like information regarding clinical trial site locations in your area,

please contact us. 

Foot Fact: 40% of adults experience foot pain at some point in their lives.